Imiquimod 5% Cream as Adjunctive Therapy For Primary, Solitary, Nodular Nasal Basal Cell Carcinomas Before Mohs Micrographic Surgery: A Randomized, Double Blind, Vehicle-Controlled Study-Reference-Cited by-同舟云学术

Imiquimod 5% Cream as Adjunctive Therapy For Primary, Solitary, Nodular Nasal Basal Cell Carcinomas Before Mohs Micrographic Surgery: A Randomized, Double Blind, Vehicle-Controlled Study

Published:2009-01 Issue:1 Volume:35 Page:24-29
ISSN:1076-0512
Container-title:Dermatologic Surgery
language:en
Short-container-title:

Author:

BUTLER DAVID F.,PAREKH PALAK K.,LENIS ARMANDO

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Dermatology,General Medicine,Surgery

Reference23 articles.

1. Basal cell carcinoma;Wong,2003

2. Trends in the presentation and treatment of basal cell carcinomas;Roenigk,1986

3. Incomplete excision of basal cell carcinoma;Farhi,2007

4. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells;Stary,2007

5. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment;Wolf,2007

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unconjugated bilirubin and its derivative ameliorate IMQ-induced psoriasis-like skin inflammation in mice by inhibiting MMP9 and MAPK pathway;International Immunopharmacology;2024-03

2. Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology;ESMO Open;2023-12

3. Advances in Topical Treatments of Cutaneous Malignancies;American Journal of Clinical Dermatology;2022-09-28

4. British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021*;British Journal of Dermatology;2021-08-13

5. A review of emerging and non-US FDA-approved topical agents for the treatment of basal cell carcinoma;Future Oncology;2021-08